Royal Bank Of Canada Has Lowered Expectations for Dyne Therapeutics (NASDAQ:DYN) Stock Price

Key Points

• Royal Bank of Canada cut Dyne Therapeutics’ price target from $35 to $30 while maintaining an “outperform” rating, implying about 47.7% upside from the prior close. Analysts overall maintain a “Moderate Buy” consensus with an average target of $32.92.
• Dyne shares opened at $20.31 after falling 16.4%; the company reported a quarterly loss of $1.08 per share, missing estimates by $0.33. Analysts expect a full-year loss of approximately $3.47 per share.
• Insiders sold more than 4.15 million shares worth nearly $99.7 million in the latest quarter, while institutional investors own 96.68% of the stock. A director’s sale of 2.16 million shares was conducted under a pre-arranged Rule 10b5-1 plan.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) had its price objective cut by Royal Bank Of Canada from $35.00 to $30.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective points to a potential upside of 47.71% from the company's previous close.

A number of other research analysts have also recently issued reports on the stock. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $37.00 target price on shares of Dyne Therapeutics in a report on Tuesday. TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a "buy" rating for the company. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an "overweight" rating for the company. Morgan Stanley reduced their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $32.92.

Dyne Therapeutics Trading Down 16.4%

Shares of DYN stock opened at $20.31 on Wednesday. The company has a market capitalization of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The business's 50 day moving average is $24.82 and its two-hundred day moving average is $20.49. Dyne Therapeutics has a twelve month low of $11.92 and a twelve month high of $27.31.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Equities analysts forecast that Dyne Therapeutics will post -3.47 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, CFO Erick Lucera sold 2,362 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer directly owned 121,563 shares in the company, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jason Rhodes sold 2,160,516 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares in the company, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,150,974 shares of company stock valued at $99,697,629 in the last quarter. Company insiders own 9.46% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new stake in Dyne Therapeutics during the 2nd quarter valued at approximately $300,000. Nykredit A S acquired a new stake in shares of Dyne Therapeutics during the second quarter worth approximately $113,000. California State Teachers Retirement System increased its stake in shares of Dyne Therapeutics by 2,049.2% in the second quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company's stock worth $66,666,000 after buying an additional 2,861,952 shares during the last quarter. Moore Capital Management LP raised its holdings in Dyne Therapeutics by 288.2% in the second quarter. Moore Capital Management LP now owns 305,794 shares of the company's stock valued at $6,792,000 after acquiring an additional 227,029 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in Dyne Therapeutics in the second quarter valued at $222,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month data from the Phase 1/2 ACHIEVE trial at the World Muscle Society and AANEM meetings beginning September 29-30. The presentation will include comparisons with a matched natural-history cohort and updated safety results, providing a near-term potential catalyst. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, with topline results expected in the first quarter of 2027. Z-basivarsen also carries FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, which could support an expedited development path. ACHIEVE trial data summary
• Neutral Sentiment: Options activity was unusually high, with traders purchasing about 20,532 call options versus average volume of roughly 464. The activity may indicate speculative expectations for a rebound or positive clinical news, but it does not establish a fundamental change in Dyne’s outlook.
• Neutral Sentiment: A Seeking Alpha analysis continued to rate DYN a buy, arguing that Dyne’s clinical program may remain differentiated despite negative developments elsewhere in the DM1 field. This represents a more constructive view than the latest brokerage downgrade.
• Negative Sentiment: JPMorgan downgraded Dyne Therapeutics (DYN) from “neutral” to “underweight” and set a $10 price target, implying substantial downside from the referenced market level. The downgrade is likely the most direct source of selling pressure today.
• Negative Sentiment: Shares fell sharply after a competing DM1 therapy failed in a Phase 3 trial. Investors appear concerned that the setback could expose challenges for the DM1 drug class or raise the bar for Dyne’s upcoming data, even though the company’s own results have not yet been reported. Report on rival DM1 trial failure
• Negative Sentiment: Several executives reported stock sales, including CEO John Cox. The filings state that the transactions were made to cover tax withholding on vested equity awards and were small relative to the insiders’ remaining holdings, reducing their significance but adding to cautious sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.